Impact Of Chronic Statin-Use On The Risk Of Post-Ercp Pancreatitis With Or Without Rectal Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Aims To assess impact of preexisting statin-use on the pancreatitis risk after endoscopic retrograde cholangio- pancreatography (ERCP) with or without rectal NSAIDs.

Methods Our retrospective study included all ERCPs performed between 01/2019-10/2020.

Cases with missing information were excluded from the final analysis.

Hyperlipasemia was defined as an increase of lipase ≥ 3 x upper limit of normal (ULN) after ERCP.

Post-ERCP pancreatitis was defined as abdominal pain with lipase ≥ 3 x ULN after ERCP and/or characteristics radiological signs.

The use of rectal NSAIDs and chronic use of statins prior to the ERCP were extracted from the patient’s files.

Results We identified 928 ERCP interventions. The final analysis included 836 interventions (49.4 % males), after the exclusion of 92 interventions performed in patients on an outpatient basis that were returned to the referring hospital immediately after ERCP.

Overall, 24.1 % of patients had statins in their premedication.

Elevated lipase ≥ 3x ULN was 19.8 % in our cohort of patients, and was similar for those with and without chronic use of statins: 20.7 % vs. 19.5 %, p=0.78.

Post-ERCP pancreatitis was observed in 4.1 % of cases and was similar regardless of the statin therapy: 3.9 % vs. 4.2 %, p=0.98.

The incidence of hyperlipasemia and post-ERCP pancreatitis was similar in chronic statin users and patients not on statins, irrespective of the combination with rectals NSAIDs (Figure)

Conclusions Chronic use of statins was not associated with hyperlipasemia and post-ERCP pancreatitis, irrespective of the combination with NSAIDs.

Fig.1

Citation Bota S, Razpotnik M, Edlinger D et al. eP345 IMPACT OF CHRONIC STATIN-USE ON THE RISK OF POST-ERCP PANCREATITIS WITH OR WITHOUT RECTAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS). Endoscopy 2021; 53: S210.

Publication History

Article published online:
19 March 2021